By now everyone has likely seen the press release issued by Dexcom announcing they have amended their agreement with Verily Google’s life sciences unit. Per that release;
“DexCom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM), and Verily, an Alphabet company, announced an amendment to the Collaboration and License Agreement surrounding the ongoing development efforts between the companies. The revised terms are intended to reinforce the companies’ mutual product development goals, while expanding options for future collaborations. The agreement also accelerates Dexcom’s efforts to advance into the Type 2 diabetes space and improves its future profitability . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.